Regeneron’s baloncibart reduced orthostatic heart rate response through Day 29 in the Phase 2 PINNACLE trial, with improvements in POTS symptoms.
Written By: Siddhi Bhadeakr, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
Regeneron Pharmaceuticals reported positive Phase 2 results on November 12, 2026, from the PINNACLE trial (NCT06593600), evaluating baloncibart (REGN7544), an investigational monoclonal antibody targeting natriuretic peptide receptor 1 (NPR1), in adults with postural orthostatic tachycardia syndrome (POTS). A single subcutaneous dose of 450 mg reduced the exaggerated heart rate response to standing and improved selected patient-reported outcomes through four weeks. The findings support further clinical evaluation of NPR1 blockade as a potential treatment strategy for POTS.
The data were presented at the American Autonomic Society’s 37th International Symposium on the Autonomic Nervous System in San Diego. Regeneron plans to initiate a potentially pivotal Phase 3 trial in the first half of 2027.
NPR1 Blockade Targets the Proposed Volume Deficit in POTS
POTS is a chronic disorder characterized by an abnormal increase in heart rate upon standing, frequently accompanied by palpitations, dizziness, fatigue, exercise intolerance, cognitive difficulties and gastrointestinal symptoms. Although its underlying cause remains unknown, reduced circulating blood volume is considered one potential contributor.
Baloncibart is designed to block NPR1, the receptor through which natriuretic peptides signal. By inhibiting this pathway, the antibody is intended to increase circulating blood volume and reduce the compensatory heart rate response associated with standing. Regeneron describes it as a first-in-class NPR1-blocking antibody. No FDA-approved treatment is currently available for POTS.
PINNACLE Evaluated Single Doses Against Placebo
The randomized, double-blind, placebo-controlled Phase 2 PINNACLE study evaluated single subcutaneous doses of baloncibart 150 mg (n=27) and 450 mg (n=28), compared with placebo (n=27), in 82 adults with POTS.
The primary endpoint was the change in heart rate from lying down to standing (ΔHR) at Day 8, while Day 29 ΔHR was a secondary endpoint. Symptoms and functional outcomes were assessed using the Living with POTS Questionnaire (LWPQ), a patient-reported outcome instrument under development by Regeneron in line with FDA patient-focused drug development guidance.
No formal hypothesis testing was prespecified; therefore, reported p-values are nominal and the findings should be considered exploratory.
Heart Rate Reduction Persisted Longer With the 450 mg Dose
Baloncibart 450 mg reduced ΔHR relative to placebo by 11.4 beats per minute (bpm) at Day 8 (nominal p=0.0007) and 7.4 bpm at Day 29 (nominal p=0.0124). The 150 mg dose produced a 9.5 bpm reduction at Day 8 (nominal p=0.0045), but the effect was not maintained at Day 29.
The persistence of the heart rate response with 450 mg, compared with the shorter-lived effect at 150 mg, suggests a potentially more sustained pharmacodynamic effect at the higher dose. However, the small sample and exploratory statistical framework do not establish a definitive dose-response relationship.
Patient-Reported Improvements Were Not Consistent Across All Domains
At Day 29, the 450 mg dose produced numerical improvements across all three LWPQ domains compared with placebo. The least-squares mean differences in change from baseline were −12.9 points for orthostatic symptoms (nominal p=0.0096), −13.8 points for physical functioning (nominal p=0.0073) and −8.7 points for activities of daily living (nominal p=0.1035).
The improvements in orthostatic symptoms and physical functioning reached nominal statistical significance, whereas the activities-of-daily-living result did not. No obvious improvement across the three domains was observed with the 150 mg dose.
These findings provide an early indication that the physiological response may translate into improvements in symptoms and daily functioning. However, the LWPQ remains under development, and these results require confirmation using an appropriately validated outcome measure.
Biomarker Changes Support the Proposed Mechanism
At Day 8, both doses produced increases in NT-proBNP and reductions in standing norepinephrine and haemoglobin. Regeneron described these changes as consistent with the anticipated plasma-volume expansion following NPR1 blockade.
Standing systolic blood pressure also increased at Day 29. Mean changes from baseline were 8.7 mmHg, reaching 118.8 mmHg, with 450 mg and 5.4 mmHg, reaching 114.0 mmHg, with 150 mg.
Together, these findings support the proposed pharmacological mechanism, although plasma-volume expansion was not reported as a directly measured outcome.
Safety Findings and Phase 3 Considerations
Single doses up to 450 mg were generally well tolerated. Treatment-emergent adverse events (TEAEs), mostly mild or moderate, occurred in 48.1% of placebo recipients, 66.7% of the 150 mg group and 67.9% of the 450 mg group. The only severe TEAE occurred with placebo.
Two serious TEAEs were reported: headache in the 150 mg group and syncope in the 450 mg group. No TEAE led to treatment discontinuation. The numerically higher overall TEAE incidence in both treatment groups, alongside blood pressure changes and the serious syncope event, warrants continued safety monitoring.
Clinical Interpretation
PINNACLE provides early proof-of-concept for NPR1 blockade in POTS by demonstrating changes in orthostatic heart rate, selected patient-reported outcomes and biomarkers consistent with the proposed volume-expansion mechanism. The persistence of the 450 mg response through Day 29 is an important development signal.
However, the findings come from only 82 participants, a single-dose study and a four-week efficacy assessment, without prespecified formal hypothesis testing. The inconsistent LWPQ results and ongoing development of the questionnaire further limit conclusions about clinical benefit. Phase 3 studies will need to establish the durability of response with repeat dosing, the appropriate dosing regimen, long-term safety and whether physiological improvements translate into sustained functional benefits across the heterogeneous POTS population.
References
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms, Regeneron Pharmaceuticals, 12 November 2026
Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients with Postural Orthostatic Tachycardia Syndrome (POTS) (PINNACLE), ClinicalTrials.gov ID NCT06593600
Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient’s Voice in Medical Product Development and Regulatory Decision Making, U.S. Food and Drug Administration, FDA.gov
About the Writer
Siddhi Rajendra Bhadekar(Linkedin) is an M.Pharm professional with expertise in medical and scientific writing, literature review, publication writing, and evidence synthesis, supported by four peer-reviewed publications.
She brings working knowledge of ICH-GCP, MedDRA, pharmacovigilance, ADR/AE reporting, clinical data management, and regulatory documentation.
With experience across pharmaceutical R&D, Quality Control, and Quality Assurance, she combines scientific research skills with strong attention to accuracy and detail.
Her background in manuscript development, publication planning, and scientific communication enables her to translate complex healthcare information into clear, reliable content.